Cases
Mallinckrodt Public Limited Company (NYSE: MNK)
Securities Class Action
Overview
Overview
- Date:
- 11/10/2015
- Company Name:
- Mallinckrodt PLC
- Stock Symbol:
- MNK
- Status:
- Closed/Complete
NEW YORK, November 10, 2015 – Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Mallinckrodt Public Limited Company (NYSE: MNK) investors concerning whether the company’s officers and board of directors violated the federal securities laws.
On November 9, 2015, analyst firm Citron Research issued a report that described Mallinckrodt’s abuse of the pharmaceutical reimbursement system, and stated that Mallinckrodt has “significantly more downside” than rival Valeant Pharmaceuticals International, Inc. and is “a far worse offender” of the reimbursement system.
Following this news, the company’s stock fell $11.88 per share, or 17%, to close at $58.01 on November 9, 2015.
If you purchased Mallinckrodt securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On November 9, 2015, analyst firm Citron Research issued a report that described Mallinckrodt’s abuse of the pharmaceutical reimbursement system, and stated that Mallinckrodt has “significantly more downside” than rival Valeant Pharmaceuticals International, Inc. and is “a far worse offender” of the reimbursement system.
Following this news, the company’s stock fell $11.88 per share, or 17%, to close at $58.01 on November 9, 2015.
If you purchased Mallinckrodt securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.